Immunotherapy in the treatment of non-small cell lung cancer

Raghav Sundar, Richie Soong, ByoungChul Cho, Julie R. Brahmer, Ross A. Soo

Research output: Contribution to journalReview article

81 Citations (Scopus)

Abstract

Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalLung Cancer
Volume85
Issue number2
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Non-Small Cell Lung Carcinoma
Immunotherapy
Immunologic Monitoring
Neoplasms
Immune System
Therapeutics
Biomarkers

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Cite this

Sundar, Raghav ; Soong, Richie ; Cho, ByoungChul ; Brahmer, Julie R. ; Soo, Ross A. / Immunotherapy in the treatment of non-small cell lung cancer. In: Lung Cancer. 2014 ; Vol. 85, No. 2. pp. 101-109.
@article{04bd7458583140b6b4553cbf972c13dd,
title = "Immunotherapy in the treatment of non-small cell lung cancer",
abstract = "Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.",
author = "Raghav Sundar and Richie Soong and ByoungChul Cho and Brahmer, {Julie R.} and Soo, {Ross A.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.lungcan.2014.05.005",
language = "English",
volume = "85",
pages = "101--109",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Sundar, R, Soong, R, Cho, B, Brahmer, JR & Soo, RA 2014, 'Immunotherapy in the treatment of non-small cell lung cancer', Lung Cancer, vol. 85, no. 2, pp. 101-109. https://doi.org/10.1016/j.lungcan.2014.05.005

Immunotherapy in the treatment of non-small cell lung cancer. / Sundar, Raghav; Soong, Richie; Cho, ByoungChul; Brahmer, Julie R.; Soo, Ross A.

In: Lung Cancer, Vol. 85, No. 2, 01.01.2014, p. 101-109.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Immunotherapy in the treatment of non-small cell lung cancer

AU - Sundar, Raghav

AU - Soong, Richie

AU - Cho, ByoungChul

AU - Brahmer, Julie R.

AU - Soo, Ross A.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.

AB - Advances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.

UR - http://www.scopus.com/inward/record.url?scp=84904112296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904112296&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2014.05.005

DO - 10.1016/j.lungcan.2014.05.005

M3 - Review article

C2 - 24880938

AN - SCOPUS:84904112296

VL - 85

SP - 101

EP - 109

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -